Molecular-based choice of cancer therapy: Realities and expectations

Clinica Chimica Acta

Volumn 379, Issue 1-2, 2007, Pages 1-13

  Imyanitov, Evgeny N ^a   Moiseyenko, Vladimir M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Amplification; Cancer therapy; Expression; Mutation; Predictive markers; SNP

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABELSON KINASE; ANTHRACYCLINE DERIVATIVE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; IMATINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RITUXIMAB; STEM CELL FACTOR; TAMOXIFEN; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DNA POLYMORPHISM; DRUG TOLERABILITY; EXCISION REPAIR; HUMAN; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 33847637537     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.01.006     Document Type: Review

References (153)

1. Chabner B.A., and Roberts Jr. T.G. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5 (2005) 65-72
2. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice in oncology. seventh ed. (2005), Lippincott Williams and Wilkins
3. Robert J., Vekris A., Pourquier P., and Bonnet J. Predicting drug response based on gene expression. Crit Rev Oncol/Hematol 51 (2004) 205-227
4. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol/Hematol 54 (2005) 171-196
5. Marsh S., and McLeod H.L. Cancer pharmacogenetics. Br J Cancer 90 (2004) 8-11
6. Dervieux T., Meshkin B., and Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 573 (2005) 180-194
7. Innocenti F., and Ratain M.J. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 75 (2004) 495-500
8. Innocenti F., Vokes E.E., and Ratain M.J. Irinogenetics: what is the right star?. J Clin Oncol 24 (2006) 2221-2224
9. Toffoli G., Veronesi A., Boiocchi M., and Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 11 (2000) 373-374
10. Ulrich C.M., Yasui Y., Storb R., et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 (2001) 231-234
11. Chiusolo P., Reddiconto G., Casorelli I., et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13 (2002) 1915-1918
12. Toffoli G., Russo A., Innocenti F., et al. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103 (2003) 294-299
13. Aschele C., Lonardi S., and Monfardini S. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28 (2002) 27-47
14. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8 (2003) 132-138
15. Watters J.W., and McLeod H.L. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603 (2003) 99-111
16. Ciccolini J., Evrard A., and Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 4 (2004) 71-81
17. Formentini A., Henne-Bruns D., and Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 389 (2004) 405-413
18. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 (2004) 939-950
19. Kawakami K., Graziano F., Watanabe G., et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11 (2005) 3778-3783
20. Stohlmacher J. Pharmacogenetics in gastrointestinal tumors. Onkologie 28 (2005) 435-440
21. Ochiai T., Nishimura K., Noguchi H., et al. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118 (2006) 3084-3088
22. Kweekel D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31 (2005) 90-105
23. Rosell R., Cobo M., Isla D., et al. Applications of genomics in NSCLC. Lung Cancer 50 Suppl 2 (2005) S33-S40
24. Liu L., and Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12 (2006) 328-331
25. Coon J.S., Marcus E., Gupta-Burt S., et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8 (2002) 1061-1067
26. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 (2002) 1107-1116
27. MacGrogan G., Rudolph P., de Mascarel I., et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 89 (2003) 666-671
28. Park K., Kim J., Lim S., and Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39 (2003) 631-634
29. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
30. Tanner M., Isola J., Wiklund T., et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 (2006) 2428-2436
31. Rouzier R., Rajan R., Wagner P., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 102 (2005) 8315-8320
32. Seve P., Mackey J., Isaac S., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4 (2005) 2001-2007
33. Seve P., Isaac S., Tredan O., et al. Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11 (2005) 5481-5486
34. Ferrandina G., Zannoni G.F., Martinelli E., et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12 (2006) 2774-2779
35. Kim S.J., Miyoshi Y., Taguchi T., et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11 (2005) 8425-84230
36. Urano N., Fujiwara Y., Doki Y., et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28 (2006) 375-381
37. Di Leo A., Cardoso F., Durbecq V., et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol 7 (2002) 245-253
38. Pusztai L., Rouzier R., Wagner P., and Symmans W.F. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. Drug Resist Updat 7 (2004) 325-331
39. Jirstrom K., Stendahl M., Ryden L., et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65 (2005) 8009-8016
40. Doan T., and Massarotti E. Rituximab. Drugs Today (Barc) 41 (2005) 785-797
41. Ross J.S., Fletcher J.A., Linette G.P., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
42. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
43. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 9 (2004) 271-281
44. Giaccone G., and Rodriguez J.A. EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nat Clin Pract Oncol 2 (2005) 554-561
45. Imyanitov E.N., Kuligina E.Sh., Belogubova E.V., Togo A.V., and Hanson K.P. Mechanisms of lung cancer. Drug Discov Today Dis Mech 2 (2005) 213-223
46. Chan S.K., Gullick W.J., and Hill M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 42 (2006) 17-23
47. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
48. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
49. Lee W., Lockhart A.C., Kim R.B., and Rothenberg M.L. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10 (2005) 104-111
50. Sadee W., and Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14 (2005) R207-R214 [Spec No 2]
51. Undevia S.D., Gomez-Abuin G., and Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5 (2005) 447-458
52. Walgren R.A., Meucci M.A., and McLeod H.L. Pharmacogenomic discovery approaches: will the real genes please stand up?. J Clin Oncol 23 (2005) 7342-7349
53. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 23 (2005) 533-537
54. McLeod H.L., and Yu J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Investig 21 (2003) 630-640
55. *3C. Pharmacogenetics 9 (1999) 641-650
56. Relling M.V., Hancock M.L., Boyett J.M., Pui C.H., and Evans W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 (1999) 2817-2823
57. Beutler E., Gelbart T., and Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A 95 (1998) 8170-8174
58. Monaghan G., Ryan M., Seddon R., Hume R., and Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347 (1996) 578-581
59. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
60. Marcuello E., Altes A., Menoyo A., Del Rio E., Gomez-Pardo M., and Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91 (2004) 678-682
61. Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., and Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10 (2004) 5151-5159
62. Massacesi C., Terrazzino S., Marcucci F., et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106 (2006) 1007-1016
63. Han J.Y., Lim H.S., Shin E.S., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24 (2006) 2237-2244
64. Carlini L.E., Meropol N.J., Bever J., et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11 (2005) 1226-1236
65. Mathijssen R.H., de Jong F.A., van Schaik R.H., et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96 (2004) 1585-1592
66. Longley D.B., Harkin D.P., and Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 (2003) 330-338
67. Innocenti F., and Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 38 (2002) 639-644
68. Desai A.A., Innocenti F., and Ratain M.J. Pharmacogenomics: road to anticancer therapeutics nirvana?. Oncogene 22 (2003) 6621-6628
69. Mandola M.V., Stoehlmacher J., Muller-Weeks S., et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63 (2003) 2898-2904
70. Ulrich C.M., Bigler J., Velicer C.M., Greene E.A., Farin F.M., and Potter J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomark Prev 9 (2000) 1381-1385
71. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
72. Marcuello E., Altes A., del Rio E., Cesar A., Menoyo A., and Baiget M. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 (2004) 733-737
73. Morganti M., Ciantelli M., Giglioni B., et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41 (2005) 2176-2183
74. Lecomte T., Ferraz J.M., Zinzindohoue F., et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10 (2004) 5880-5888
75. Etienne M.C., Chazal M., Laurent-Puig P., et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20 (2002) 2832-2843
76. Tsuji T., Hidaka S., Sawai T., et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9 (2003) 3700-3704
77. Jakobsen A., Nielsen J.N., Gyldenkerne N., and Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 (2005) 1365-1369
78. Dotor E., Cuatrecases M., Martinez-Iniesta M., et al. Tumor thymidylate synhase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24 (2006) 1603-1611
79. Cohen V., Panet-Raymond V., Sabbaghian N., Morin I., Batist G., and Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9 (2003) 1611-1615
80. Masters J.R., and Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 3 (2003) 517-525
81. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
82. Zhou W., Gurubhagavatula S., Liu G., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10 (2004) 4939-4943
83. Liu D., O'Day S.J., Yang D., et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11 (2005) 1237-1246
84. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 (2005) 6212-6217
85. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., and Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 (2001) 8654-8658
86. Stoehlmacher J., Ghaderi V., Iobal S., et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21 (2001) 3075-3079
87. Imyanitov E.N., Togo A.V., and Hanson K.P. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett 204 (2004) 3-14
88. Pianezza M.L., Sellers E.M., and Tyndale R.F. Nicotine metabolism defect reduces smoking. Nature 393 (1998) 750
89. Sellers E.M., Tyndale R.F., and Fernandes L.C. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov Today 8 (2003) 487-493
90. *11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12 (2002) 299-306
91. Nakajima M., and Yokoi T. Cancer pharmacogenomics: achievements in basic research. Int J Clin Oncol 10 (2005) 14-19
92. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
93. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
94. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 (2005) 249-258
95. Mathijssen R.H., and van Schaik R.H. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer 42 (2006) 141-148
96. Henningsson A., Marsh S., Loos W.J., et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11 (2005) 8097-8104
97. Stoehlmacher J., Park D.J., Zhang W., et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
98. Goekkurt E., Hoehn S., Wolschke C., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286
99. Sweeney C., McClure G.Y., Fares M.Y., et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60 (2000) 5621-5624
100. Gibson N.J. The use of real-time PCR methods in DNA sequence variation analysis. Clin Chim Acta 363 (2006) 32-47
101. Hiratsuka M., Sasaki T., and Mizugaki M. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin Chim Acta 363 (2006) 177-186
102. Rebbeck T.R., Ambrosone C.B., Bell D.A., et al. SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomark Prev 13 (2004) 681-687
103. Savage S.A., and Chanock S.J. Using germ-line genetic variation to investigate and treat cancer. Drug Discov Today 9 (2004) 610-618
104. Altshuler D., Brooks L.D., Chakravarti A., Collins F.S., Daly M.J., and Donnelly P. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
105. Libra M., Navolanic P.M., Talamini R., et al. Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 4 (2004) 11
106. Gonen M., Hummer A., Zervoudakis A., et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21 (2003) 406-412
107. Ichikawa W., Takahashi T., Suto K., et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91 (2004) 1245-1250
108. Kidd E.A., Yu J., Li X., Shannon W.D., Watson M.A., and McLeod H.L. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 11 (2005) 2612-2619
109. Adlard J.W., Richman S.D., Seymour M.T., and Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3 (2002) 75-82
110. Vincenzi B., Cesa A.L., Santini D., et al. Predictive factors for response to chemotherapy in colorectal cancer patients. Crit Rev Oncol/Hematol 52 (2004) 45-60
111. Toi M., Atiqur Rahman M., Bando H., and Chow L.W. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6 (2005) 158-166
112. Ichikawa W., Uetake H., Shirota Y., et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89 (2003) 1486-1492
113. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
114. Smorenburg C.H., Peters G.J., van Groeningen C.J., et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 17 (2006) 35-42
115. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
116. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
117. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
118. Warnecke-Eberz U., Metzger R., Miyazono F., et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10 (2004) 3794-3799
119. Joshi M.B., Shirota Y., Danenberg K.D., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11 (2005) 2215-2221
120. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
121. Ma S., Egyhazi S., Ueno T., et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 89 (2003) 1517-1523
122. Ohno T., Hiraga J., Ohashi H., et al. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 83 (2006) 341-347
123. Pollack I.F., Hamilton R.L., Sobol R.W., et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24 (2006) 3431-3437
124. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin Chem 51 (2005) 494-503
125. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol 26 (2005) 281-293
126. Piccart-Gebhart M.J. Anthracyclines and the tailoring of treatment for early breast cancer. N Engl J Med 354 (2006) 2177-2179
127. Braybrooke J.P., Levitt N.C., Joel S., et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res 9 (2003) 4682-4688
128. Kamath K., Wilson L., Cabral F., and Jordan M.A. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280 (2005) 12902-12907
129. Mozzetti S., Ferlini C., Concolino P., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11 (2005) 298-305
130. Hasegawa S., Miyoshi Y., Egawa C., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9 (2003) 2992-2997
131. Iwao-Koizumi K., Matoba R., Ueno N., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23 (2005) 422-431
132. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
133. Cappuzzo F., Varella-Garcia M., Shigematsu H., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23 (2005) 5007-5018
134. Kaye F.J. A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?. J Natl Cancer Inst 97 (2005) 621-623
135. Takano T., Ohe Y., Sakamoto H., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
136. Kwak E.L., Jankowski J., Thayer S.P., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12 (2006) 4283-4287
137. Moroni M., Sartore-Bianchi A., Benvenuti S., Artale S., Bardelli A., and Siena S. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. Ann Oncol 16 (2005) 1848-1849
138. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
139. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11 (2005) 4741-4748
140. Brenton J.D., Carey L.A., Ahmed A.A., and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 23 (2005) 7350-7360
141. Hayes D.F. Prognostic and predictive factors revisited. Breast 14 (2005) 493-499
142. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 (2005) 488-492
143. Murphy N., Millar E., and Lee C.S. Gene expression profiling in breast cancer: towards individualising patient management. Pathology 37 (2005) 271-277
144. Reid J.F., Lusa L., De Cecco L., et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97 (2005) 927-930
145. Ioannidis J.P. Microarrays and molecular research: noise discovery?. Lancet 365 (2005) 454-455
146. Ein-Dor L., Zuk O., and Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103 (2006) 5923-5928
147. Liu E.T. Molecular oncodiagnostics: where we are and where we need to go. J Clin Oncol 21 (2003) 2052-2055
148. Iqbal S., Stoehlmacher J., and Lenz H.J. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Investig 22 (2004) 762-773
149. Imyanitov E.N., Suspitsin E.N., Buslov K.G., et al. Isolation of nucleic acids from paraffin-embedded archival tissues and other difficult sources. In: Kieleczawa J. (Ed). The DNA book: protocols and procedures for the modern molecular biology laboratory (2006), Jones and Bartlett Publishers 85-97
150. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101 (2004) 9393-9398
151. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 (2003) 3983-3988
152. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., and Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5 (2005) 899-904
153. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 (2005) 275-284